Back to School: How biopharma can reboot drug development. Access exclusive analysis here

J&J partners with Second Genome, launches innovation center

The Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) partnered with Second Genome Inc. (San Bruno, Calif.) to characterize the role of bacterial

Read the full 240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE